Used as a potent inhibitor in the treatment of type 2 diabetes, this compound targets the SGLT2 (sodium-glucose co-transporter 2) protein in the kidneys. By inhibiting SGLT2, it reduces glucose reabsorption, leading to increased excretion of glucose through urine and lowering blood sugar levels. Its high selectivity enhances efficacy while minimizing off-target effects. The compound is formulated in oral dosage forms and shows favorable pharmacokinetics, including good bioavailability and sustained action. It is investigated for cardiovascular benefits in diabetic patients, such as reduced risk of heart failure and improved renal outcomes.